J0593
J0593 – Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when dr · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 3 NDCs crosswalked per 1 mg $88.216/unit ASP+6%
📋 J0593 summary
J0593 is a HCPCS Level II J-code used to bill lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct..., billed per 1 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J0593: Takhzyro
Code J0593
Billing unit 1 mg Payment limit $88.216/unit NDC-Crosswalk 3
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0593
DescriptorInjection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
Billing unit1 mg
Payment limit / unit$88.216
Est. ASP / unit$83.223 est.
Mapped NDCs3
Data periodQ3 2026
Last updated2026-09-20
💊 About Lanadelumab-flyo injection DRUG GUIDE
Takhzyro (lanadelumab-flyo) is used to prevent attacks of hereditary angioedema (HAE) — a condition that causes sudden, severe swelling in places like the hands, feet, face, airway, or gut.
It is approved for adults and children 2 years of age and older.Takhzyro is a preventive (prophylactic) treatment, not a rescue medication.
It is given by subcutaneous (under-the-skin) injection on a regular schedule to reduce how often HAE attacks happen.
Clinical overview from our editorial drug guide for Lanadelumab-flyo injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$88.216
Est. ASP / unit
$83.223 est.
Est. after 2% sequester
$86.452
HCPCS dosage
1 mg
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeP — Payment change
Effective date2024-01-01
Date added2019-10-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0593 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0593 WITH EST. MEDICARE PAY
3 NDCs map to J0593. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($88.216/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 47783-0645-01 | TAKHZYRO lanadelumab-flyo 150 mg/mL SOLUTION | Takeda | 1 SYRINGE, GLASS in 1 CARTON (47783-645-01... | 150 mg/mL | 150 | $13,232.40 | — | ● Active | CMS + PDAC |
| 47783-0646-01 | TAKHZYRO lanadelumab-flyo 300 mg/2mL SOLUTION | Takeda | 1 SYRINGE, GLASS in 1 CARTON (47783-646-01... | 300 mg/2mL | 300 | $26,464.80 | — | ● Active | CMS + PDAC |
| 47783-0644-01 | TAKHZYRO lanadelumab-flyo 300 mg/2mL INJECTION, SOLUTION | Takeda | 1 VIAL, GLASS in 1 CARTON (47783-644-01)... | 300 mg/2mL | 150 | $13,232.40 | — | Obsolete | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$0.00
Medicare paid
$0.03
Submitted services
311
Denial rate
100.0%
Submitted charges
$0.01
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J0593
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-09-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
3 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
No reportable utilization
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0593 billing FAQ
What is HCPCS code J0593?
J0593 is a HCPCS Level II J-code used to bill Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered) under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0593?
One unit of J0593 represents 1 mg. Report the number of units equal to the dose administered divided by 1 mg.
How many units of J0593 should I bill?
Divide the dose administered by the code's unit size (1 mg) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0593?
The Medicare Part B payment limit is $88.216 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $86.452 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0593?
3 NDCs currently map to J0593 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0593 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.